Please login to the form below

Not currently logged in
Email:
Password:

Richard Chin joins board of ImmunoCellular Therapeutics

Adds drug development experience as company looks to advance brain tumour vaccine

Former CEO of the non-profit pharma firm OneWorld Health Dr Richard Chin has joined the board of directors at ImmunoCellular Thereapeutics.

Chin, who currently serves on the adjunct faculty of the University of California, San Francisco School of Medicine, will also become chair of the compensation committee at ImmunoCellular – a US-based clinical-stage company developing immune-based therapies for the treatment of cancer.

“His extensive experience in drug development will be valuable as the company advances its phase II clinical trial of ICT-107,” said ImmunoCellular's chairman Dr John Yu, referencing the company's cancer vaccine currently in development for the brain tumour glioblastoma multiforme.

Chin spent left OneWorld Health in 2011 after spending three years leading the organisation, which aims to develop new treatments for neglected diseases. It is largely funded by the Bill and Melinda Gates Foundation.

Prior to this role, he was president and CEO of biopharma Oxigene from 2006 to 2008 and he has also held senior roles at Elan and Genentech.

19th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics